Matching-Adjusted Indirect Comparisons of Lorlatinib Versus Chemotherapy for Patients With Second-Line or Later Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer-Reference-Cited by-同舟云学术

Matching-Adjusted Indirect Comparisons of Lorlatinib Versus Chemotherapy for Patients With Second-Line or Later Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer

Published:2023-01 Issue:1 Volume:26 Page:64-70
ISSN:1098-3015
Container-title:Value in Health
language:en
Short-container-title:Value in Health

Author:

Smith Sarah,Albuquerque de Almeida Fernando,Inês Monica,Iadeluca Laura,Cooper Miranda

Funder

Pfizer

Publisher

Elsevier BV

Subject

Public Health, Environmental and Occupational Health,Health Policy

Reference20 articles.

1. Epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase/oncogene or C-Ros oncogene 1 (ALK/ROS1) fusions inflict non-small cell lung cancer (NSCLC) female patients older than 60 years of age;Ke;Med Sci Monit,2018

2. Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario;Addeo;Crit Rev Oncol Hematol,2018

3. Non-small-cell lung cancer (NSCLC) harboring ALK translocations: clinical characteristics and management in a real-life setting: a French retrospective analysis (GFPC 02-14 study);Auliac;Target Oncol,2017

4. Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date;Akamine;Onco Targets Ther,2018

5. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up;Planchard;Ann Oncol,2018

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysis;BMC Cancer;2024-02-08

2. A Retrospective, Multicenter, Observational Study to Evaluate Clinical Outcomes of Lorlatinib After Alectinib in Patients With ALK-Positive NSCLC in Japan;JTO Clinical and Research Reports;2023-05